Trial Description

Title

Retrospective analysis of imaging modalities acquired during clinical diagnosis of patients with clinical suspected neurodegenerative Parkinsonian syndrome

Trial Acronym

MOPET

URL of the trial

[---]*

Brief Summary in Lay Language

The aim of the study consists in retrospective analysis of imaging modalities acquired in patients with clinical suspected neurodegenerative Parkinsonian syndrome for correlation between different modalities and with clinical parameter. Potential progression parameter will be identified.

Brief Summary in Scientific Language

We object to characterize patients with clinical suspected Parkinsonian syndrome by multimodal imaging parameter together with clinical scoring. Midbrain atrophy, retinal layer thickness and tau quantification will be analyzed and correlated with clinical scoring.

Do you plan to share individual participant data with other researchers?

[---]*

Description IPD sharing plan

[---]*

Organizational Data

- DRKS-ID: **DRKS00016920**
- Date of Registration in DRKS: **2019/03/18**
- Date of Registration in Partner Registry or other Primary Registry: **[---]***
- Investigator Sponsored/Initiated Trial (IST/IIT): **yes**
- Ethics Approval/Approval of the Ethics Committee: **Approved**
- (leading) Ethics Committee Nr.: **19-022 , Ethik-Kommission der Medizinischen Fakultät der Ludwig-Maximilians-Universität München**

Secondary IDs

Health condition or Problem studied

- ICD10: **G20 - Parkinson disease**

Interventions/Observational Groups

- Arm 1: **Quantitative analysis of cMRI and/or OCT and/or tau-PET in patients with probable or possible progressive supranuclear palsy**
- Arm 2: **Quantitative analysis of cMRI and/or OCT and/or tau-PET in patients with probable or possible tau-negative Parkinsonian syndrome**
- Arm 3: **Quantitative analysis of cMRI and/or OCT and/or tau-PET in historically examined healthy controls**

Characteristics

- Study Type: **Non-interventional**
- Study Type Non-Interventional: **Other**
- Allocation: **Non-randomized controlled trial**
- Blinding: **[---]***
- Who is blinded: **[---]***
- Control: **Historical, Other**
- Purpose: **Basic research/physiological study**
- Assignment: **Other**
- Phase: **N/A**
- Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): **N/A**

Primary Outcome

For patients with cMRT the midbrain diameter and the midbrain to pons ratio will be acquired.

For patients with OCT the thickness of retinal layers will be accessed.

For patients with tau-PET the regional signal in defined target regions (midbrain, globus pallidus, nucleus dentatus, frontal cortex) will be quantified.

The quantification will be performed retrospectively and linked to the acqusition

date. Specific software will be used for quantification (i.e. PMOD Technologies, Basel, Switzerland).

The primary endpoint consists in correlation of cMRI, OCT, and tau-PET quantification with disease severity for patients with Progressive Supranuclear Palsy.

Secondary Outcome

Quantification of cMRI, OCT, and tau-PET will be compared between patients with probable and possible Progressive Supranuclear Palsy, patients with probable tau-negative Parkinsonian syndrome and healthy controls.

Countries of recruitment

- DE **Germany**

Locations of Recruitment

- Medical Center **LMU München, München**
- Medical Center **Universtitäsklinikum Köln, Köln**
- Medical Center **Universitätsklinikum Leipzig, Leipzig**

Recruitment

- Planned/Actual: **Planned**
- (Anticipated or Actual) Date of First Enrollment: **2019/03/31**
- Target Sample Size: **50**
- Monocenter/Multicenter trial: **Multicenter trial**
- National/International: **National**

Inclusion Criteria

- Gender: **Both, male and female**
- Minimum Age: **40 Years**
- Maximum Age: **90 Years**

Additional Inclusion Criteria

clinical suspected neurodegenerative Parkinsonian Syndrome and acquisition of at least one of the following modalities: cMRI, OCT, tau-PET

Exclusion criteria

other non-neurodegenerative CNS diseases like glioma or stroke

Addresses

- **Primary Sponsor**

Klinik und Poliklinik für Nuklearmedizin, LMU München
Mr. Dr. Matthias Brendel
Marchioninistraße 15
81377 München
Germany

Telephone: **089440074650**
Fax: **089440074676**
E-mail: **matthias.brendel at med.uni-muenchen.de**
URL: **https://www.uni-muenchen.de/index.html**

- **Contact for Scientific Queries**

Klinik und Poliklinik für Nuklearmedizin, LMU München
Mr. Dr. Matthias Brendel
Marchioninistraße 15
81377 München
Germany

Telephone: **089440074650**
Fax: **089440074676**
E-mail: **matthias.brendel at med.uni-muenchen.de**
URL: **https://www.uni-muenchen.de/index.html**

- **Contact for Public Queries**

Klinik und Poliklinik für Nuklearmedizin, LMU München
Mr. Dr. Matthias Brendel
Marchioninistraße 15
81377 München
Germany

Telephone: **089440074650**
Fax: **089440074676**
E-mail: **matthias.brendel at med.uni-muenchen.de**
URL: **https://www.uni-muenchen.de/index.html**

Sources of Monetary or Material Support

- **Institutional budget, no external funding (budget of sponsor/PI)**

Institutional budget, no external funding (budget of sponsor/PI)

Klinik und Poliklinik für Nuklearmedizin, LMU München
Mr. Dr. Matthias Brendel
Marchioninistraße 15
81377 München
Germany

Telephone: **089440074650**
Fax: **089440074676**
E-mail: **matthias.brendel at med.uni-muenchen.de**
URL: **https://www.uni-muenchen.de/index.html**

Status

- Recruitment Status: **Recruiting planned**
- Study Closing (LPLV): **[---]***

Trial Publications, Results and other documents

- Approval of ethics comm. (mandatory for transfer to Studybox) **Ethikvotum**
- trial protocol (mandatory for transfer to Studybox) **Studienprotokoll**

** This entry means the parameter is not applicable or has not been set.*

**** This entry means that data is not displayed due to insufficient data privacy clearing.*